Xeris Biopharma Holdings, Inc. Common Stock XERS
i
Market dataready · fetched 2026-11-13T02:54:12.112Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T23:21:53.721865882Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-13T02:54:11.604549+00:00
Xeris Biopharma Holdings, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 11.88 | 446.9% | 38.9% | |||
| 25Δ | 13.28 | 365.6% | 30.5% | |||
| 30Δ | 14.48 | 301.0% | 23.5% | |||
| 35Δ | 24.58 | 395.3% | 57.8% | 15.44 | 253.9% | 18.0% |
| 40Δ | 16.14 | 223.2% | 14.3% | |||
| 45Δ | 16.64 | 200.5% | 11.7% | |||
| 50Δ | 17.14 | 177.8% | 9.1% | |||
| 55Δ | 17.59 | 158.2% | 6.9% | |||
| 60Δ | 17.89 | 146.3% | 5.8% | |||
| 65Δ | 18.19 | 134.5% | 4.6% | |||
| 70Δ | 18.49 | 122.7% | 3.5% | |||
| 75Δ | 18.80 | 110.9% | 2.4% | |||
| 80Δ | 19.43 | 110.9% | 1.6% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 11.88
- IV
- 446.9%
- B/E move
- 38.9%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 13.28
- IV
- 365.6%
- B/E move
- 30.5%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 14.48
- IV
- 301.0%
- B/E move
- 23.5%
35Δ
- Pseudo strike
- 24.58
- IV
- 395.3%
- B/E move
- 57.8%
- Pseudo strike
- 15.44
- IV
- 253.9%
- B/E move
- 18.0%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 16.14
- IV
- 223.2%
- B/E move
- 14.3%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 16.64
- IV
- 200.5%
- B/E move
- 11.7%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 17.14
- IV
- 177.8%
- B/E move
- 9.1%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 17.59
- IV
- 158.2%
- B/E move
- 6.9%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 17.89
- IV
- 146.3%
- B/E move
- 5.8%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 18.19
- IV
- 134.5%
- B/E move
- 4.6%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 18.49
- IV
- 122.7%
- B/E move
- 3.5%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 18.80
- IV
- 110.9%
- B/E move
- 2.4%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 19.43
- IV
- 110.9%
- B/E move
- 1.6%
Options history
Table
| Date | IV (%) |
|---|---|
| 81.96% | |
| 89.13% | |
| 99.29% | |
| 98.04% | |
| 101.85% | |
| 121.26% | |
| 108.66% | |
| 110.49% | |
| 113.67% | |
| 86.73% |
Drug Manufacturers - Specialty & Generic
ZTS
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
More →ACB
Description unavailable
More →AKBA
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of kidney therapies for patients with kidney disease. The company is…
More →ALKS
Alkermes plc, a biopharmaceutical company, researches, develops and markets pharmaceutical products to address the unmet medical needs of patients in various therapeutic areas in…
More →AMLX
Amylyx Pharmaceuticals Inc (AMLX) is an innovative biopharmaceutical company at the forefront of developing transformative therapies for neurodegenerative diseases, particularly…
More →AMPH
Description unavailable
More →